摘要
目前临床上大多使用Child-Pugh分级来评估肝癌患者的肝功能及治疗相关的预后预测,但由于Child-Pugh分级评价指标中的腹水及白蛋白水平存在关联,且腹水及肝性脑病分度存在较大主观性,降低了评分的客观性和精确性。ALBI分级是Philip J. Johnson等人于2014年提出的评估肝功能的新方法,是一个仅包含白蛋白和胆红素两项客观指标的统计模型。本文就近年来ALBI分级在肝癌患者疗效和预后的评估、ALBI的改良及与其他预后评分的结合予以总结并进行综述。
In clinical practice, the Child-Pugh grade is widely used to assess liver function and predict treatment-related prognosis in patients with hepatocellular carcinoma. However, the objectivity and accuracy of the Child-Pugh grade are compromised due to the correlation between ascites and albumin levels in the evaluation criteria, and the significant subjectivity in grading ascites and hepatic encephalopathy. The ALBI (Albumin-Bilirubin) grade, proposed by Philip J. Johnson and colleagues in 2014, is a novel method for assessing liver function, featuring a statistical model that includes only two objective indicators: albumin and bilirubin. This article summarizes and reviews the application of ALBI grading in the evaluation of therapeutic efficacy and prognosis in hepatocellular carcinoma in recent years, the modifications of ALBI, and its combination with other prognostic scores.
出处
《临床医学进展》
2024年第5期933-939,共7页
Advances in Clinical Medicine
